Altimmune (ALT) Stock Price, News & Analysis

Company Overview

Altimmune, Inc. is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose. This candidate is being advanced in collaboration with the University of Alabama at Birmingham and is supported by the National Institute of Allergy and Infectious Diseases. In parallel, Altimmune’s HepTcell program aims to treat chronic hepatitis B by eliciting targeted T-cell responses capable of clearing infected liver cells.

Altimmune’s AdCOVID™ platform uses a replication-incompetent adenovirus vector to deliver vaccine antigens directly to the nasal mucosa, and it is also under evaluation for additional respiratory pathogens, including coronaviruses. The company maintains a pipeline of preclinical programs in liver and metabolic diseases, reflecting its commitment to harnessing immunotherapy and vaccine design across multiple therapeutic areas.

The company’s leadership team combines extensive scientific expertise and operational experience in vaccine research and development. Through a strategic blend of translational science and external partnerships, Altimmune seeks to advance innovative therapies that improve patient outcomes and address global health challenges.

Key Stats

• Today's Range: $3.04 to $3.26
• 50-Day Range: $2.60 to $4.57
• 52-Week Range: $2.56 to $7.73
• Volume: 4.07 million shs
• Average Volume: 4.61 million shs
• Market Capitalization: $424.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Moderate Buy

Altimmune Stock Analysis - MarketRank™

Altimmune scored higher than 59% of companies evaluated by MarketBeat, and ranked 355th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Altimmune has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 2 sell ratings.

Upside Potential

Altimmune has a consensus price target of $18.00, representing about 463.4% upside from its current price of $3.20.

Amount of Analyst Coverage

Altimmune has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Altimmune are expected to remain at ($1.00) per share in the coming year.

Price to Earnings Ratio vs. the Market

The P/E ratio of Altimmune is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Altimmune is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Altimmune has a P/B Ratio of 1.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

22.44% of the float of Altimmune has been sold short.

Short Interest Ratio / Days to Cover

Altimmune has a short interest ratio ("days to cover") of 13.71, which indicates bearish sentiment.

Change versus previous month

Short interest in Altimmune has recently decreased by 1.76%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Altimmune does not currently pay a dividend.

Dividend Growth

Altimmune does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Altimmune this week, compared to 9 articles on an average week.

Search Interest

44 people have searched for ALT on MarketBeat in the last 30 days. This is an increase of 7% compared to the previous 30 days.

MarketBeat Follows

7 people have added Altimmune to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days.

Company Ownership

• Score: 4.3 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Altimmune in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $88,500.00 in company stock, which represents 0.0213% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Altimmune insiders have bought more of their company's stock than they have sold. Specifically, they have bought $88,500.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

1.60% of the stock of Altimmune is held by insiders.

Percentage Held by Institutions

78.05% of the stock of Altimmune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALT Stock Analysis - Frequently Asked Questions

How have ALT shares performed this year?

Altimmune's stock was trading at $3.61 at the start of the year. Since then, ALT stock has decreased by 11.5% and is now trading at $3.1950.

How were Altimmune's earnings last quarter?

Altimmune, Inc. (NASDAQ:ALT) released its quarterly earnings results on Thursday, March, 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.02. The business earned $0.03 million during the quarter, compared to the consensus estimate of $0 million. Altimmune had a negative trailing twelve-month return on equity of 49.35% and a negative net margin of 214,860.98%.
Read the conference call transcript.

When did Altimmune's stock split?

Shares of Altimmune reverse split on Friday, September 14th 2018.The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Who are Altimmune's major shareholders?

Top institutional shareholders of Altimmune include Bank of New York Mellon Corp (0.32%), Beirne Wealth Consulting Services LLC (0.32%), Janney Montgomery Scott LLC (0.13%) and Hsbc Holdings PLC (0.12%). Insiders that own company stock include David Drutz, Jerome Benedict Durso, Gregory L Weaver, Wayne Pisano, John Gill and Diane Jorkasky.
View institutional ownership trends.

How do I buy shares of Altimmune?

Shares of ALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Altimmune own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Altimmune investors own include Invesco QQQ (QQQ), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE) and SPDR S&P 500 ETF Trust (SPY).

Company Calendar

• Last Earnings: 3/05/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALT
• CIK: 1326190
• Web: altimmune.com
• Phone: (240) 654-1450
• Fax: 410-269-2601
• Employees: 50
• Year Founded: 1997

Price Target and Rating

• Average Price Target for Altimmune: $18.00
• High Price Target: $25.00
• Low Price Target: $12.00
• Potential Upside/Downside: +452.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$88.09 million
• Net Margins: -214,860.98%
• Pretax Margin: -216,521.95%
• Return on Equity: -49.35%
• Return on Assets: -41.65%

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 18.55
• Quick Ratio: 18.55

Sales & Book Value

• Annual Sales: $40 thousand
• Price / Sales: 10,603.15
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.99 per share
• Price / Book: 1.64

Miscellaneous

• Outstanding Shares: 130,100,000
• Free Float: 128,023,000
• Market Cap: $424.13 million
• Optionable: Optionable
• Beta: 0.18